Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
Sponsor: Grifols Therapeutics LLC
This PHASE3 trial investigates Polyradiculoneuropathy, Chronic Inflammatory Demyelinating and is currently completed. Grifols Therapeutics LLC leads this study, which shows 8 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Apr 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Apr 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Grifols Therapeutics LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Belgrade, Serbia, Berlin, Germany, Brno, Czechia, Buenos Aires, Argentina, Capital Federal, Argentina, Chieti, Italy, Cleveland, United States, Dallas, United States, Gdansk, Poland, Genova, Italy and 19 more location s